Categories
Politics

Jury begins deliberating in Derek Chauvin homicide trial

Former Minneapolis Police Officer Derek Chauvin and his defense attorney Eric Nelson attend the final confrontation during the Chauvin’s trial for second degree, third degree and second degree homicide in the death of George Floyd with his defense attorney Eric Nelson in Minneapolis, Minnesota , part. US April 19, 2021 in a still from video.

Reuters

Prosecutors and the defense advanced their final arguments to the jury on Monday in the murder trial of Derek Chauvin, the white ex-police officer who was accused of killing George Floyd last May.

The anonymous, multiracial jury can now deliberate until a unanimous verdict is reached.

Violent police violence against black men broke out in Minneapolis and elsewhere.

“You can believe your eyes,” Prosecutor Jerry Blackwell told the jury. A video of Chauvin with his knee to Floyd’s neck was a central aspect of the prosecution.

“Why is it necessary to continue to lethally restrain a man who is defenseless, who is handcuffed, who does not resist, who does not breathe, who has no pulse?” Blackwell added.

“It was like he was in a truck. It was like being squeezed into a truck,” said prosecutor Steve Schleicher.

Schleicher pushed back the defense’s arguments that Floyd died as a result of his underlying health conditions and drug use.

“You don’t have to believe the amazing coincidence that after this nine-minute restriction of 29 seconds, Floyd” chose this moment to die of heart disease, “said Schleicher.

Eric Nelson, Chauvin’s attorney, began his arguments to get the jury to think deeply about whether Chauvin was acting within the law.

“The standard is not what the officer should have done in the circumstances. It is not what the officer could have done otherwise,” Nelson said.

Nelson said the standard was what a reasonable officer would do in any circumstance he or she faces.

“All the evidence shows that Mr. Chauvin thought he was following his training,” said Nelson. “There is absolutely no evidence that the officer chauvin intentionally and deliberately used unlawful violence.”

The case is the best-known litigation involving a white officer accused of killing a black man in recent years.

Immediately after the arguments concluded, Nelson asked Judge Peter Cahill to issue a mistrial, citing comments from Rep. Maxine Waters, D-Calif. Waters called on protesters on Saturday to “become more confrontational” if the jury concludes that they are not guilty.

Cahill turned down a lawsuit but said, “I give you that Congressman Waters may have given you something on appeal.”

“I wish elected officials would stop talking about this case, especially in ways that do not respect the rule of law, the judiciary or our role,” said Cahill.

White House press secretary Jen Psaki was briefed on the case during a press conference Monday afternoon. Psaki declined to say whether President Joe Biden would be personally disappointed if Chauvin was found not guilty.

The final arguments put forward two very different versions of what happened on May 25, the day Floyd died after Chauvin and other Minneapolis police officers tried to arrest him on suspicion of passing a forged bill.

The Floyd family and Reverend Al Sharpton gesticulate as they arrive at the Hennepin County Government Center to finalize testimony on the trial of former police officer Derek Chauvin, charged with the murder of George Floyd in Minneapolis, Minnesota, USA in April 19, 2021.

Nicholas Pfosi | Reuters

Prosecutors and their experts have told the jury that Chauvin killed Floyd by cutting off his airway with the police officer’s knee while the black suspect was handcuffed and pegged to the floor for about 9 minutes.

During the trial, they made extensive use of video footage recorded by bystanders showing Floyd pleading for his life and telling officers he could not breathe.

The prosecutor also called Dr. Martin Tobin, a pulmonologist and respiratory science expert, who testified that Floyd had died of a lack of oxygen.

“A healthy person exposed to what Mr. Floyd was exposed to would have died,” Tobin told the jury.

Schleicher relied heavily on Tobin’s earlier statements in his final arguments.

“It was very clear that George Floyd died of low oxygen levels,” he said.

The indictment was led by Matthew Frank, an attorney with the Minnesota Attorney General. Two other prosecutors, Schleicher and Blackwell, shared the final arguments.

The defense led by Nelson argued that Floyd died as a result of the large amount of the drug fentanyl that he was taking prior to his arrest in addition to his underlying medical problems. An autopsy also found methamphetamine in Floyd’s system.

Nelson also tried to label the crowd of spectators who were there on May 25 as a threat to the arresting officers and to make their work more difficult. He has argued that Chauvin’s knee may not be on Floyd’s neck, but rather was on his back.

Nelson also highlighted obvious discrepancies between the prosecution’s arguments and Dr. Andrew Baker, Hennepin County’s medical examiner, who performed Floyd’s autopsy.

Baker ruled Floyd’s death was murder, but did not establish that the cause of death was asphyxiation or lack of oxygen as prosecutors alleged.

“The sub-dual law enforcement, reluctance, and neck compression were simply more than Mr. Floyd could endure due to this heart condition,” Baker said.

Dr. David Fowler, a former Maryland chief medical officer called on by the defense, testified that carbon monoxide fumes from a nearby vehicle may have contributed to his death in addition to his enlarged heart, high blood pressure, and drug use.

Chauvin has been charged with second degree murder, third degree murder, and second degree manslaughter. Each of these allegations requires prosecutors to show that chauvin was a “major contributing factor” to Floyd’s death.

Second degree murder is sentenced to a maximum of 40 years in prison. Third degree murder is 25 years maximum and manslaughter charges are 10 years maximum. Actual penalties are often below the legal maximums.

Jurors are instructed that if they have reasonable doubts about Chauvin’s guilt, they must not vote guilty. A unanimous jury is required to convict any of the cases.

The jury consists of 14 people, including two deputies who can be dismissed before the deliberations. The diverse group consists of two multiracial women, three black men, one black woman, six white women, and two white men.

The trial comes as tensions are high. On April 11, while the clashes were ongoing, police officer Kimberly Potter Daunte Wright, a 20-year-old black man, fatally shot and killed during a traffic obstruction in nearby Brooklyn Center and sparked protests.

Potter stepped back, claiming she thought she was using a taser. She was charged with second degree manslaughter.

– The Associated Press contributed to this report

Subscribe to CNBC Pro for the live TV stream, deep insights and investment analysis.

Categories
Health

Oxford to launch human problem trial to review immune response

Caroline Nicolls will receive an injection of the Moderna Covid-19 vaccine administered by Nurse Amy Nash at Madejski Stadium in Reading, west of London, on April 13, 2021.

STEVE PARSONS | AFP | Getty Images

LONDON – Oxford University researchers announced the start of a Human Challenge study on Monday to better understand what happens when people who have already contracted the coronavirus become infected for the second time.

The researchers will investigate what kind of immune response can prevent people from becoming infected with Covid-19 again and examine how the immune system reacts to the virus a second time.

Little is currently known about what happens to people who had the virus the second time they were infected.

The experiment is carried out in two phases with different participants in each phase. The first phase is slated to begin this month and the second phase is slated to begin in summer.

In medical research, Human Challenge studies are controlled studies in which participants are intentionally exposed to a pathogen or beetle to study the effects.

“Challenge studies tell us things that other studies cannot because, unlike natural infections, they are tightly controlled,” said Helen McShane, chief investigator for the study and professor of vaccinology in the Department of Pediatrics at Oxford University.

“If we re-infect these participants, we will know exactly how their immune systems responded to the first COVID infection, when exactly the second infection occurs, and how much virus they have,” said McShane.

It is hoped that the study will help improve scientists’ basic understanding of the virus and develop tests that can reliably predict whether people will be protected.

What happens in each phase?

In the first phase, up to 64 volunteers between the ages of 18 and 30 who were previously infected naturally will be re-exposed to the virus under controlled conditions.

Researchers will oversee attendees’ care while they perform CT scans of the lungs and MRI scans of the heart while isolating in a specially designed suite for at least 17 days.

All participants must be fit, healthy and have fully recovered from their initial infection with Covid to minimize the risk.

Study participants will only be released from the quarantine unit if they are no longer infected and there is a risk of the disease spreading.

A view of the City of London on a clear day.

Vuk Valcic | SOPA pictures | LightRocket via Getty Images

In the second phase of the experiment, two different areas are examined.

“First we will very carefully define the basic immune response of the volunteers before we infect them. We will then infect them with the dose of virus selected from the first study and measure how much virus we can detect after infection. We will then.” to be able to understand what kind of immune responses protect against re-infection, “said McShane.

“Second, we will measure the immune response several times after infection so we can understand what immune response is being generated by the virus,” she added.

The entire study period is 12 months, including at least eight follow-up appointments after discharge.

“This study has the potential to change our understanding by providing high-quality data on how our immune systems react to a second infection with this virus,” said Shobana Balasingam, senior research advisor on vaccines at Wellcome, a nonprofit that funded the study.

“The results could have important implications for the future management of COVID-19, influencing not only vaccine development but research into the range of effective treatments that are also badly needed,” Balasingam said.

Categories
Health

Pfizer begins trial on infants and younger youngsters

A healthcare worker prepares a vaccination for Pfizer coronavirus disease (COVID-19) in Los Angeles, California on January 7, 2021.

Lucy Nicholson | Reuters

Pfizer announced that it has started a clinical trial testing the Covid-19 vaccine in healthy children aged 6 months to 11 years. This is a critical step in gaining regulatory approval to vaccinate young children and fight the pandemic.

The first participants in the study have already made their recordings, which were developed in collaboration with the German drug manufacturer BioNTech, New York-based Pfizer announced on Thursday. In the first phase, 144 children are to be enrolled.

In the first phase of the study, the company will determine the preferred dosage level for three age groups – between 6 months and 2 years, 2 and 5 years, and between 5 and 11 years. The children will first receive a dose of 10 micrograms of the vaccine before gradually moving on to higher doses, Pfizer said. Participants also have the option of ingesting 3 micrograms doses. The adult Covid vaccine requires two shots that contain 30 micrograms per dose.

Researchers will then evaluate the safety and effectiveness of the selected dose levels in the next phase of the study, with participants being randomly selected to receive the vaccine or a placebo, the company said. After a six-month follow-up visit, children who received a placebo will have the option to receive the vaccine.

“Pfizer has extensive experience developing clinical trials of vaccines in children and infants and is committed to improving the health and well-being of children through well-designed clinical trials,” the company said in a statement.

Pfizer’s vaccine has already been approved for use in the United States by Americans 16 and older. Clinical studies testing the vaccine in children whose immune systems may react differently than adults are still to be completed.

Vaccinating children is critical to ending the pandemic, say public health officials and infectious disease experts. The US is unlikely to achieve herd immunity – or if enough people in a given community have antibodies to a given disease – before children can be vaccinated. According to the government, children make up around 20% of the US population.

In late January, Pfizer announced that it had fully registered the Covid-19 vaccine study for children ages 12-15. The company announced Thursday that the data in this cohort was “encouraged” and hopes to provide more details about the study. soon.”

Moderna, which also has a US-approved vaccine, announced on March 16 that it has started testing its shot in children under the age of 12. Moderna started a study in December testing children aged 12 to 17 years.

Johnson & Johnson plans to test its single-shot vaccine in infants and even newborns after it was first tested in older children, according to the New York Times.

The Chief Medical Officer of the White House, Dr. Anthony Fauci, speaking to a House committee earlier this month, said the U.S. could vaccinate older children against Covid-19 starting this fall, while elementary school-age children may get their shots early next year.

Pfizer’s announcement comes two days after the start of an early-stage clinical trial of an experimental oral antiviral drug that could be used at the first sign of Covid infection.

Health experts say the world will still need a slew of drugs and vaccines to end the pandemic that has infected more than 30 million Americans and killed at least 545,282 people in just over a year, according to Johns Hopkins University.

Categories
World News

AstraZeneca points up to date part three trial knowledge

A healthcare worker prepares to inject a vaccine against AstraZeneca coronavirus disease (COVID-19).

Eloisa Lopez

AstraZeneca released updated Phase 3 trial data for its Covid-19 vaccine on Wednesday after asking accuracy questions related to a preliminary report from its US study earlier this week.

The company now says its vaccine is 76% effective against symptomatic virus cases. A press release published on Monday reported a symptomatic efficacy rate of 79%. The updated report claims the shot is 100% effective against serious illness and hospital stays.

A group of US health officials criticized the company over the past few days for claiming that they are collecting data to make the results seem more favorable.

The National Institute of Allergy and Infectious Diseases announced Tuesday that the UK-based company may have included information from its US findings that provided an “incomplete view of efficacy data”.

AstraZeneca said at the time that the numbers were based on a “pre-determined interim analysis” and promised to share the updated analysis in the coming days.

Dr. Anthony Fauci, Chief Medical Officer and White House Director at NIAID, described the situation as “unfortunate” and said it was likely that AstraZeneca would issue a modified statement.

“This is really what you call an easy mistake as it is most likely a very good vaccine,” Fauci told ABC’s Robin Roberts on Good Morning America Tuesday. “Something like that … really creates doubts about the vaccines and maybe adds to hesitation. It wasn’t necessary.”

The updated results include data from 190 symptomatic cases in more than 32,000 participants – an increase of around 50 symptomatic cases studied compared to the dataset published Monday.

The results suggest that the vaccine is more effective than previously thought in patients aged 65 and over, with a newly reported efficacy rate of 85% for this population versus 80% previously reported.

AstraZeneca reiterated Wednesday that the vaccine was “well tolerated” among participants and that no safety concerns were identified.

AstraZeneca has faced a separate backlash over the past few weeks due to reports of blood clotting related to its vaccine, which is already approved and used by dozen of countries around the world. Several European nations have suspended and then resumed use of the vaccine after independent safety reviews.

– CNBC’s Berkeley Lovelace Jr., Sam Meredith, and Steve Kopack contributed to this report.

Categories
Health

Pfizer begins early stage scientific trial testing oral antiviral drug

Pfizer said Tuesday it had started an early clinical trial of an experimental oral antiviral drug for Covid-19.

The New York-based company announced that the Phase 1 study of the drug PF-07321332 will be conducted in the United States. The drug belongs to a class of drugs called protease inhibitors, and it works by blocking an enzyme that the virus needs to replicate in human cells.

Protease inhibitors are used to treat other viral pathogens such as HIV and hepatitis C.

“Fighting the COVID-19 pandemic requires both preventive vaccination and targeted treatment of those who become infected with the virus,” Pfizer’s chief scientist Mikael Dolsten said in a press release. “Given the way SARS-CoV-2 is mutating and the ongoing global impact of COVID-19, it is likely that access to therapeutic options will be critical both now and after the pandemic.”

The study comes as Pfizer is also working on an intravenously administered protease inhibitor known as PF-07304814. This drug is currently in a Phase 1b clinical trial in patients hospitalized with Covid-19.

A person walks past the Pfizer building in New York City on March 2, 2021.

Carlo Allegri | Reuters

Pfizer already has an approved vaccine in the US with German drug maker BioNTech, but health experts say the world will need a slew of drugs and vaccines to end the pandemic that is infecting more than 29.8 million Americans and is coming soon Has killed at least 542,991 people over a year, according to the Johns Hopkins University.

Preclinical studies have shown that the oral drug, the first orally ingested protease inhibitor for Covid-19 to be studied in clinical trials, has “strong” antiviral activity against the virus.

Because the drug is taken orally, it can be used outside of hospitals for people newly infected with the virus. The researchers hope the drugs will prevent the disease from getting worse and keep people out of the hospital.

Pfizer said it will provide more details on the drug at the Spring American Chemical Society meeting on April 6.

Categories
Business

U.S. Well being Officers Query AstraZeneca Vaccine Trial Outcomes

This US trial, which was attended by more than 32,000 participants, was the largest test of its kind for the shot. The results, AstraZeneca released on Monday, came from an interim look at the data after 141 Covid-19 cases occurred in volunteers.

The company had only announced on Tuesday how up-to-date this data was. This information is important because sometimes a more up-to-date look at clinical trial results may reveal different efficacy and safety.

If the analysis was done on data from a month or two ago, it is possible that a more recent look may give a different picture of the vaccine’s effectiveness and safety. The company has announced that it will provide the FDA with a more comprehensive and up-to-date dataset than it released on Monday. Although no clinical study is large enough to rule out extremely rare side effects, AstraZeneca reported that its study did not identify any serious safety issues.

The new data may have arrived too late to make a big difference in the United States, where the vaccine has not yet been approved and is not expected to be available until May. By then, federal officials say, there will be enough vaccine doses for all adults in the country from the three already approved vaccines: Pfizer-BioNTech, Moderna, and Johnson & Johnson.

Even so, the better-than-expected results have been seen as an encouraging turn for AstraZeneca’s shot, whose low cost and simple storage requirements have made it an important part of the quest to vaccinate the world.

The results were also believed to allay concerns about the AstraZeneca vaccine in Europe. Regulators there said the shot was “safe and effective” last week after conducting a review after a small number of people who had recently been vaccinated developed blood clots and abnormal bleeding. The US study found no evidence of such problems, although some real-world safety issues can only be identified when a drug or vaccine is widely used.

Millions of people have received the AstraZeneca shot worldwide, including more than 17 million in the UK and the European Union, almost all without serious side effects. To increase public confidence, many European political leaders have received the injections in the past few days. The AstraZeneca vaccine was also given to executives in South Korea, Taiwan and Thailand last week.

Categories
Business

79% efficient in U.S. trial

A healthcare professional will prepare a dose of the Oxford / AstraZeneca Covid-19 vaccine at the vaccine center at the Brighton Center in Brighton, southern England on January 26, 2021.

Ben Stensall | AFP | Getty Images

LONDON – The results of a large US study showed that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% effective against serious illness and hospitalization.

The vaccine’s safety and efficacy analysis published on Monday was based on 32,449 participants from a Phase 3 study.

By comparison, Moderna’s vaccine was found to be greater than 94% effective in preventing Covid, and Pfizer-BioNTech’s vaccine was found to be 95% effective.

AstraZeneca announced that it will continue to analyze the data and prepare for the primary analysis to be submitted to the US Food and Drugs Administration for emergency approval in the coming weeks.

It comes shortly after a flood of countries temporarily suspended the use of the shot after blood clots were reported in some people who had been vaccinated. Health experts sharply criticized the move, citing a lack of data, while analysts expressed concerns about the impact on vaccine uptake as the virus continues to spread.

Germany, France, Italy and Spain, among others, have resumed use of the Oxford-AstraZeneca vaccine after the European Medicines Agency found the shot was both safe and effective in its initial investigation into possible side effects.

The World Health Organization and the International Society on Thrombosis and Hemostasis have recommended that countries continue to use the Oxford-AstraZeneca vaccine.

AstraZeneca said in a press release Monday that an independent board had not identified any safety concerns related to the shot. With the help of an independent neurologist, they also performed a specific check for blood clots as well as cerebral venous sinus thrombosis (CVST), an extremely rare blood clot in the brain.

The Data Safety Monitoring Board “found no increased risk of thrombosis or events characterized by thrombosis in the 21,583 participants who received at least one vaccine dose. The specific search for CVST found no events in this study.”

AstraZeneca’s shares traded nearly 1% early this morning.

“Urgently needed” additional vaccination option

Ann Falsey, Professor of Medicine in the School of Medicine at the University of Rochester, USA, and Co-Lead Principal Investigator for the study, said, “This analysis validates the AstraZeneca COVID-19 vaccine as a much-needed additional vaccine option and offers adults confidence all ages can benefit from protection against the virus. “

The drug company said the shot was well tolerated and its effectiveness was consistent in terms of ethnicity and age.

In particular, the Oxford-AstraZeneca shot was 80% effective in preventing Covid in participants 65 and over.

A healthcare worker receives the Oxford-AstraZeneca Covid-19 vaccine at Chang Gung Memorial Hospital in Taipei, Taiwan on Monday March 22, 2021. Taiwan started vaccinating against coronavirus today.

I-Hwa Cheng | Bloomberg | Getty Images

“These results add to the growing evidence showing that this vaccine is well tolerated and highly effective against all degrees of COVID-19 and across all ages,” said Mene Pangalos, executive vice president of BioPharmaceuticals R&D at AstraZeneca. in a statement.

“We are confident that this vaccine can play an important role in protecting millions of people worldwide from this deadly virus,” said Pangalos.

Among the participants in the interim analysis, around 20% were 65 years of age and older, while around 60% had comorbidities that were associated with an increased risk of progression to severe Covid such as diabetes or heart disease.

Categories
Business

Michael Spavor, Canadian Accused of Spying, Stands Trial in China

A Chinese court on Friday opened a lawsuit against a Canadian businessman who has been in custody for more than two years on charges of espionage. This case sparked a worldwide outcry and called on the US to intervene.

A court in Dandong, a northeastern Chinese city, tried the Canadian Michael Spavor, who campaigned for cultural travel to North Korea before he was arrested in late 2018, in retaliation for Canada’s decision to arrest a leading Chinese technology executive United States request.

The court said in a concise statement that Mr. Spavor had been tried for espionage and “illegally providing state secrets abroad”. It was said that a verdict would be pronounced at a later date.

As a sign of China’s efforts to control the trial, the authorities banned the public and the news media from participating in the trial. A group of 10 diplomats from eight countries, including Canada and the United States, tried to gain access to the trial in Dandong, a coastal city near China’s border with North Korea, but were turned away. The court said the trial, which lasted about two hours, was held in private because it contained state secrets.

“We are deeply concerned about the lack of transparency in these processes,” said Jim Nickel, a senior official at Canada’s Embassy in Beijing who attempted to participate in the process, in a statement.

Another Canadian, Michael Kovrig, a former diplomat who was also arrested in 2018, is expected to stand trial in Beijing on Monday.

Since their detention, Mr. Spavor and Mr. Kovrig have been at the center of a heated international dispute between China, Canada and the United States.

China, accusing western countries of attempting to thwart its rise as a tech superpower, is urging the US to end a full-blown fraud case against Meng Wanzhou, chief financial officer of Chinese tech giant Huawei. The United States, requesting Ms. Meng’s extradition, has asked China to release Mr. Spavor and Mr. Kovrig.

“The trials of the two Michaels are revenge for Ms. Meng,” said Guy Saint-Jacques, a veteran Canadian ambassador to China who was Mr. Kovrig’s boss when he was first secretary at the Canadian embassy in Beijing. “It’s a message to Canada and the world: ‘Don’t mess with China.'”

The Canadians question was about to come up when senior government officials from Biden met their Chinese counterparts in Anchorage on Thursday. Friends and relatives of Mr Spavor and Mr Kovrig have urged President Biden and Canada’s Prime Minister Justin Trudeau to take steps to ensure their release.

American officials said Friday that they were “deeply alarmed” by China’s decision to continue the trials of Mr. Spavor and Mr. Kovrig. “We stand side by side with Canada in demanding their immediate release,” a US embassy spokesman in Beijing said in a statement.

Any compromise with Beijing could be elusive as China has shown no signs of withdrawal but has used the persecution of the two men to project an image of strength and demand that the United States withdraw its extradition request for Ms. Meng.

“Beijing makes it clear that the two Michaels with Chinese characteristics will be tried: closed to the public and the media,” said Diana Fu, professor of political science at the University of Toronto. “His actions leave little doubt as to who will be the ultimate decider of the fate of the Canadians – the Chinese Communist Party, not Biden, not Trudeau.”

The detention of the two men has led to tougher measures against China in Canada. According to a recent poll by the Angus Reid Institute, a leading polling company, only 14 percent of Canadians view China positively. A majority see the Chinese government’s liberation of the two Canadians as a prerequisite for re-establishing relations.

“There is a backlash against China in Canada and the process will only exacerbate attitudes,” said Gordon Houlden, director emeritus of the University of Alberta’s China Institute. He added that the case of the two Michaels underscored the limited leverage of a middle power like Canada in the face of an economic and political giant like China.

Legal experts and human rights defenders have denounced China’s treatment of Canadians and accused Chinese officials of using “hostage diplomacy”. The two men, held in separate prisons in northern China, are largely cut off from the world and sometimes forced to go months without diplomatic visits. They had limited access to defense lawyers.

“Like so many cases where Chinese authorities try to silence a critic or settle a bill, these cases have nothing to do with the law,” said Sophie Richardson, China director at Human Rights Watch.

As a self-described consultant, Mr. Spavor ran an organization in Dandong promoting cultural trips to North Korea. There he made high-ranking contacts and once met North Korea’s leader Kim Jong-un. In 2013, Mr. Spavor helped organize a visit to North Korea for Dennis Rodman, the former NBA star.

“Michael is just an ordinary Canadian businessman,” his family said in a pre-trial statement on Friday. “He loved living and working in China and would never have done anything to harm the interests of China or the Chinese people. We stand by Michael and keep his innocence in this difficult situation. “

Claire Fu and Albee Zhang have contributed to the research.

Categories
Health

Elizabeth Holmes trial probably delayed as a result of she’s pregnant

Elizabeth Holmes, founder and former executive director of Theranos, arrives for a hearing in the U.S. District Court in the Federal Building of Robert F. Peckham in San Jose, California on Monday, November 4, 2019.

Yichuan Cao | NurPhoto | Getty Images

Former Theranos CEO Elizabeth Holmes, whose criminal trial is due to begin in July, is asking for a delay because she is pregnant.

In a trial on Friday, her defense attorneys and prosecutors asked Judge Edward Davila to postpone the start of her trial for six weeks to begin August 31, 2021.

“On March 2, 2021, the defendant’s attorney notified the government that the defendant is pregnant and is expected to be due in July 2021,” Holmes prosecutors and attorneys write. “Both parties agree that in view of this development it is not possible to start the process on July 13, 2021.”

Further details were not immediately available.

The process has already been postponed three times due to the Covid-19 pandemic.

Holmes’ legal team was ready to address the issue of mental health as part of their defense strategy. In a previous court case, Holmes’ attorneys wrote that they intend to produce evidence “relating to a mental illness or a mental defect or other psychological condition of the defendant relating to the subject of guilt”.

This would be the expert testimony of Dr. Mindy Mechanic, a professor of clinical psychology at California State University Fullerton, who, according to the university’s website, “focuses on the psychosocial consequences of violence, trauma and victimization, with an emphasis on violence against women and other forms of violence interpersonal violence. “

The judge gave federal prosecutors the opportunity to self-examine Holmes’ mental health and to be examined by two experts, a psychologist and a psychiatrist.

Holmes and her former COO Sunny Balwani each face a dozen charges of fraud and 20 years in prison for falsely claiming that Theranos technology can perform dozens of blood tests on just a drop or two of blood.

The Silicon Valley startup was once valued at $ 9 billion before it closed in 2018.

Categories
Health

NIH halts trial of Covid plasma remedy after researchers discovered no profit

Convalescent plasma from a patient with recovered coronavirus disease (COVID-19) is seen at the Central Seattle Donor Center of Bloodworks Northwest during the outbreak in Seattle, Washington on April 17, 2020.

Lindsey Wasson | Reuters

The National Institutes of Health announced Tuesday that they had abandoned a study testing convalescent plasma in patients with mild to moderate Covid-19 symptoms after an independent panel of experts concluded it was unlikely to be beneficial.

The independent data and safety watchdog met on February 25 to review the data and found that while plasma treatment did no harm, it was unlikely to be of benefit to this patient population, the NIH said in a press release. After the meeting, the DSMB recommended that the NIH no longer enroll new patients in the study, the agency said.

Scientists and public health officials had previously said they were skeptical that convalescent plasma would be an effective treatment for patients with Covid, even after the Food and Drug Administration issued emergency approval for the treatment in August and former President Donald Trump said it was ” Breakthrough “denounced. “

At the time, Dr. Scott Gottlieb, a former FDA commissioner, said the treatment could help patients but “doesn’t look like a home run”. He agreed that convalescent plasma “certainly” met the standard for an emergency permit “in the context of a public health emergency.”

The plasma, taken from patients who have recovered from Covid-19 and who have developed antibodies to the virus, is infused into sick patients. Scientists had hoped it would help boost immune systems in these patients to fight the virus.

In January, REMAP-CAP, an international clinical trial investigating possible treatments for Covid, discontinued the study testing convalescent blood plasma after the study’s examiners found no benefit. The decision by REMAP-CAP was made after an initial analysis of more than 900 critically ill study participants in the intensive care unit showed that treatment with the product did not noticeably improve the health of the patients.

The NIH study was conducted in 47 US hospitals emergency departments and had 511 of the 900 participant recruitment targets enrolled. After study participants received either the plasma or a placebo, the researchers tracked whether participants needed additional emergency or urgent treatment, had to be hospitalized, or died within 15 days of the start of the study.